Kai Kupferschmidt. (2021, March 16). “I’m not here to give you the outcome of any scientific review”, says EMA director Emer Cooke at start of press conference on AstraZeneca vaccine safety. ‘I’m here to explain the steps in the process, what we’re doing, and when you can expect us to come to a conclusion.’ [Tweet]. @kakape. https://twitter.com/kakape/status/1371811123197001729

the Guardian. ‘Small Number of Facebook Users Responsible for Most Covid Vaccine Skepticism – Report’, 16 March 2021. http://www.theguardian.com/technology/2021/mar/15/facebook-study-covid-vaccine-skepticism.

A Few People Developed a Rare Blood Disorder, Immune Thrombocytopenia, After Getting a COVID Vaccine | Health.com. (n.d.). Retrieved March 17, 2021, from https://www.health.com/condition/infectious-diseases/coronavirus/rare-blood-disorder-covid-vaccine-thrombocytopenia

Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

Steinhauser, G. (2021, February 7). Rollout of AstraZeneca Covid-19 Vaccine Halted in South Africa After Study. Wall Street Journal. https://www.wsj.com/articles/astrazeneca-vaccine-doesnt-protect-against-mild-and-moderate-cases-from-south-africa-strain-11612700385

Staff, R. (2021, February 5). AstraZeneca expects U.S. trial results in next 4-6 weeks, research chief says. Reuters. https://www.reuters.com/article/uk-health-coronavirus-astrazeneca-usa-idUSKBN2A522V

Variants, 3 New Covid Vaccines, and Contested Efficacy Claims: A Month of Seismic Shifts and Confusion. (2021, January 31). Absolutely Maybe. https://absolutelymaybe.plos.org/2021/01/31/variants-3-new-covid-vaccines-and-contested-efficacy-claims-a-month-of-seismic-shifts-and-confusion/

ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults | University of Oxford. (n.d.). Retrieved February 18, 2021, from https://www.ox.ac.uk/news/2021-02-07-chadox1-ncov-19-provides-minimal-protection-against-mild-moderate-covid-19-infection

Staff, R. (2021, February 6). AstraZeneca thinks shot can stop severe disease from South Africa COVID variant. Reuters. https://www.reuters.com/article/uk-health-coronavirus-astrazeneca-respon-idUKKBN2A60S2

November 19: “Randomisation and control in the age of coronavirus?” (Stephen Senn). (2020, October 30). PhilStatWars. https://phil-stat-wars.com/2020/10/30/november-19-randomisation-and-control-in-the-age-of-coronavirus-stephen-senn/

ReconfigBehSci. (2020, October 31). RT @learnfromerror: PHIL STAT FORUM NOVEMBER 19; STEPHEN SENN ‘Randomisation and Control in the Age of Coronavirus?’ https://t.co/hqT8GWTqC… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1323311706609721344

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

Matthews, D. (2020, May 20). How exposing healthy volunteers to Covid-19 for vaccine testing would work. Vox. https://www.vox.com/future-perfect/2020/5/20/21258725/covid-19-human-challenge-trials-vaccine-update-sars-cov-2

Callaway, E. (2020). The race for coronavirus vaccines: A graphical guide. Nature, 580(7805), 576–577. https://doi.org/10.1038/d41586-020-01221-y